Cyberonics Announces FDA Approval of Aspire High Capacity Generator
Cyberonics, Inc. (Nasdaq: CYBX) today announced that the AspireHC generator for use in vagus nerve stimulation therapy was approved by the United States Food and Drug Administration (FDA) for commercial release.
The AspireHC generator represents the fifth generation of VNS Therapy technology. This product incorporates greater functionality for the benefit of patients and their physicians, including longer battery life, improved electronics and simplified features for programming.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.